Thus, the value of BRAF mutation as an additional risk factor in stage III other than stage IV TCC could better discriminate, between patients with a worse prognosis, who could benefit from target treatments since the early stage of the disease. The gene discussed is BRAF; the disease is tarsal-carpal coalition syndrome.